Colan Totte.Co.,Ltd.
7792・Growth Market・Other Products
Business
Colantotte Co., Ltd. is a QOL (quality-of-life) improvement company whose core business is the development and sale of home-use magnetic therapy devices (controlled medical devices) using its proprietary "alternating N-pole/S-pole arrangement" permanent magnet technology. Founded in 1997, the company listed on the Tokyo Stock Exchange Mothers market (now the Growth Market) in 2021. In addition to its flagship brand "Colantotte," the company operates the sleep-focused brand "Colantotte RESNO," the women's brand "Lierrey," and the emergency contact service "CSS (Colantotte Safety System)." Its core customer base, centered on men aged 40 and above, has been expanding to include sports enthusiasts and health-conscious consumers, and the company has been raising brand awareness through contracts with prominent athletes such as figure skater Shoma Uno. Manufacturing is outsourced, and products are sold through three channels: wholesale, e-commerce, and retail.
Business Model
A fabless business model that outsources manufacturing to enhance asset efficiency while concentrating management resources on planning, development, marketing, and sales. Sales channels consist of three divisions: wholesale, e-commerce (proprietary EC site and EC malls), and retail (directly operated stores). Expansion of the e-commerce and retail divisions, which have high direct-sales ratios, directly contributes to improving gross profit margin. In FY2025 (ending September 2025), the e-commerce sales composition ratio rose to 31.5% (up from 27.2% in the previous period). The operating profit margin on sales reached 26.2%.
Company Strengths
Obtained patents for its proprietary "alternating N-pole/S-pole arrangement" technology (Japan 2014, US 2018). Acquired certification as a controlled medical device from a third-party certification body designated by the Ministry of Health, Labour and Welfare, and also holds the EU's CE marking and ISO13485 certification. The company has built technological and regulatory barriers to entry that competitors cannot easily replicate.
For FY2025 (ending September 2025), the company achieved net sales of ¥6,918 million (up 16.4% year on year), operating profit of ¥1,810 million (up 20.6% year on year), and net income of ¥1,328 million (up 29.7% year on year). Both net sales and profit reached record highs, with profit renewing its record high for eight consecutive fiscal periods. The operating margin remained at a high level of 26.2%.
As of the end of FY2025 (ending September 2025), the company held no interest-bearing debt whatsoever, and its balance of cash and cash equivalents stood at ¥2,180 million (up ¥423 million from the previous fiscal year-end). Total net assets reached ¥5,168 million, and the company maintained a sound financial structure with an equity ratio exceeding 77%. Operating cash flow was a stable ¥998 million, reflecting solid cash-generating capability.
ENVALITH's Perspective
Performance Trend
Revenue over the past five fiscal years expanded steadily from ¥3,753 million (FY2021) to ¥6,918 million (FY2025), and growth became clearly more pronounced in the interim period of FY2026 (ending September 2026) at ¥4,330 million (+34.1% YoY). Operating profit also increased to ¥1,117 million (+18.2%), maintaining profit growth. However, due to increased SG&A expenses such as advertising costs accompanying the rapid expansion of the e-commerce/retail segment (from ¥1,223 million to ¥1,849 million YoY, +51.2%), the operating profit margin declined to 25.8% (from 29.3% in the same period of the previous year). As external factors, rising health consciousness and expansion of the sports market are providing a tailwind, while high prices and a slowdown in overseas economies present downside risks to consumer sentiment. The full-year forecast (as revised) is revenue of ¥9,000 million and operating profit of ¥2,100 million.
Growth Strategy
Enhancing presence in the QOL market through a shift to direct sales via e-commerce and directly-operated store expansion, combined with strengthened marketing
Continuing to strengthen marketing activities centered on TV commercials and SNS to improve brand awareness, along with ongoing campaign initiatives. In the first half of FY2026 (ending March 2026)... [interim period], sales grew 72.8% year-on-year to ¥1,564 million, expanding its contribution to earnings as the core of the direct sales channel.
Four new stores were opened during the interim period: "Aeon Mall Sendai Uesugi" in October 2025, "Mitsui Outlet Park Okazaki" in November 2025, "LaLaport Kadoma" in December 2025, and "Nishinomiya Hankyu" in March 2026. Retail segment sales grew 77.5% year-on-year to ¥578 million.
Strengthened sales of high-value-added and premium-priced products centered on Recovery Wear, maintaining strong performance in the mail-order channel of the wholesale segment. This has contributed to maintaining a high gross profit margin of 68.5%, with product mix improvements underpinning profitability.
Actively deploying integrated marketing that combines TV commercials, newspaper advertisements, SNS, and contracted athlete events. While upfront investment in advertising expenses is pushing up SG&A expenses, the effects are becoming apparent in the form of increased store visitor numbers and expanded e-commerce sales.
Last updated: July 17, 2026